ARTICLEManagement of Antipsychotic-Induced Weight Gain Part IIRado, Jeffrey T. MD; Keim, Kathryn S. PhD, RD, LDN; Dowd, Sheila M. PhDEditor(s): Janicak, Philip G. MD; Editor Author Information Dr. Rado is Assistant Professor of Psychiatry and Internal Medicine, Dr. Keim is Professor of Clinical Nutrition, and Dr. Dowd is Assistant Professor of Psychiatry and Psychology, Rush University Medical Center, 2150 West Harrison, Chicago, IL 60612; E-mail: [email protected]. All faculty and staff in a position to control the content of this CME activity, and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity. The U.S. Food and Drug Administration has not approved the use of pharmacologic agents for the prevention or treatment of antipsychotic-induced weight gain as discussed in this article. Please consult the product's labeling for approved information. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the newsletter's website (www.psychopharmrev.com). Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. This activity expires on June 30, 2014. Psychopharm Review: July 2013 - Volume 48 - Issue 7 - p 49-56 doi: 10.1097/01.PSYPHR.0000431986.53973.d8 Buy SDC CME Test Metrics © 2013 Lippincott Williams & Wilkins, Inc.